Bristol-Myers Squibb
This article was originally published in The Gray Sheet
Executive Summary
Accounting charge of $375-435 mil. for the fourth quarter should be the final one associated with breast implant liability, the company announces Nov. 16. The charge will cover potential suits from the 6,000 women who opted out of the previously announced revised global breast implant settlement as well as payment related to the settlement itself. The company's pretax costs related to the litigation now total $4.0 bil., of which $1.1 bil. was paid through insurance